Saedis Saevarsdottir

Saedis Saevarsdottir

Auto-generated profile, based on publicly available information

Saedis Saevarsdottir

DeCODE Genetics/Amgen, Inc., Reykjavik, Iceland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EFEgil Ferkingstad
Egil Ferkingstad
PSPatrick Sulem
Patrick Sulem
BABjarni A. Atlason
Bjarni A. Atlason
GSGardar Sveinbjornsson
Gardar Sveinbjornsson
MMMagnus I. Magnusson
Magnus I. Magnusson
KSKari Stefansson
Kari Stefansson

4 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
GEGrímur Hjörleifsson Eldjárn
Grímur Hjörleifsson Eldjárn
EFEgil Ferkingstad
Egil Ferkingstad
SLSigrun H. Lund
Sigrun H. Lund
HHHannes Helgason
Hannes Helgason
OMOlafur Th. Magnusson
Olafur Th. Magnusson
KSKari Stefansson
Kari Stefansson
High-throughput proteomics platforms measuring thousands of proteins in plasma combined with genomic and phenotypic information have the power to bridge the gap between the genome and diseases. Here we performed association studies of Olink Explore 3072 data generated by the UK Biobank Pharma Proteomics Project1 on plasma samples from more than 50,000 UK Biobank participants with phenotypic and genotypic data, stratifying on British or Irish, African and South Asian ancestries. We compared the results with those of a SomaScan v4 study on plasma from 36,000 Icelandic people2, for 1,514 of whom Olink data were also available. We found modest correlation between the two platforms. Although cis protein quantitative trait loci were detected for a similar absolute number of assays on the two platforms (2,101 on Olink versus 2,120 on SomaScan), the proportion of assays with such supporting evidence for assay performance was higher on the Olink platform (72% versus 43%). A considerable number of proteins had genomic associations that differed between the platforms. We provide examples where differences between platforms may influence conclusions drawn from the integration of protein levels with the study of diseases. We demonstrate how leveraging the diverse ancestries of participants in the UK Biobank helps to detect novel associations and refine genomic location. Our results show the value of the information provided by the two most commonly used high-throughput proteomics platforms and demonstrate the differences between them that at times provides useful complementarity.

15 August 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DEdamon eisen
damon eisen
MDMelinda M. Dean
Melinda M. Dean
MBMarja A. Boermeester
Marja A. Boermeester
KFKaty J. Fidler
Katy J. Fidler
AGAnthony C. Gordon
Anthony C. Gordon
EMEmma McBryde
Emma McBryde
Background. Previous studies have shown associations between low mannose-binding lectin (MBL) level or variant MBL2 genotype and sepsis susceptibilit

22 September 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SSSaedis Saevarsdottir
Saedis Saevarsdottir
SWSara Wedrén
Sara Wedrén
MSMaria Seddighzadeh
Maria Seddighzadeh
CBCamilla Bengtsson
Camilla Bengtsson
AWAnnmarie Wesley
Annmarie Wesley
LKLars Klareskog
Lars Klareskog
Objective: To determine whether cigarette smoking influences the response to treatment in patients with early rheumatoid arthritis (RA).Methods: We retrieved clinical information about patients entering the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) early RA cohort from 1996 to 2006 (n = 1,998) who were also in the Swedish Rheumatology Register (until 2007). Overall, 1,430 of the 1,621 registered patients were followed up from the time of inclusion in the EIRA cohort. Of these, 873 started methotrexate (MTX) monotherapy at inclusion, and 535 later started treatment with a tumor necrosis factor (TNF) inhibitor as the first biologic agent. The primary outcome was a good response according to the European League Against Rheumatism criteria at the 3‐month visit. The influence of cigarette smoking (current or past) on the response to therapy was evaluated by logistic regression, with never smokers as the referent group.Results: Compared with never smokers, current smokers were less likely to achieve a good response at 3 months following the start of MTX (27% versus 36%; P = 0.05) and at 3 months following the start of TNF inhibitors (29% versus 43%; P = 0.03). In multivariate analyses in which clinical, serologic, and genetic factors were considered, the inverse associations between current smoking and good response remained (adjusted odds ratio [OR] for MTX response 0.60 [95% CI 0.39–0.94]; adjusted OR for TNF inhibitor response 0.52 [95% CI 0.29–0.96]). The lower likelihood of a good response remained at later followup visits. Evaluating remission or joint counts yielded similar findings. Past smoking did not affect the chance of response to MTX or TNF inhibitors. Evaluating the overall cohort, which reflects all treatments used, current smoking was similarly associated with a lower chance of a good response (adjusted ORs for the 3‐month, 6‐month, 1‐year, and 5‐year visits 0.61, 0.65, 0.78, 0.66, and 0.61, respectively).Conclusion: Among patients with early RA, current cigarette smokers are less likely to respond to MTX and TNF inhibitors.

25 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSValgerdur Steinthorsdottir
Valgerdur Steinthorsdottir
RMRalph McGinnis
Ralph McGinnis
NWNicholas O. Williams
Nicholas O. Williams
LSLilja Stefansdottir
Lilja Stefansdottir
GTGudmar Thorleifsson
Gudmar Thorleifsson
KSKari Stefansson
Kari Stefansson
Preeclampsia is a serious complication of pregnancy, affecting both maternal and fetal health. In genome-wide association meta-analysis of European and Central Asian mothers, we identify sequence variants that associate with preeclampsia in the maternal genome atZNF831/20q13 andFTO/16q12. These are previously established variants for blood pressure (BP) and theFTOvariant has also been associated with body mass index (BMI). Further analysis of BP variants establishes that variants atMECOM/3q26,FGF5/4q21 andSH2B3/12q24 also associate with preeclampsia through the maternal genome. We further show that a polygenic risk score for hypertension associates with preeclampsia. However, comparison with gestational hypertension indicates that additional factors modify the risk of preeclampsia.

1 March 2011 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SSSaedis Saevarsdottir
Saedis Saevarsdottir
HWHelena Wallin
Helena Wallin
MSMaria Seddighzadeh
Maria Seddighzadeh
SESofia Ernestam
Sofia Ernestam
PGPierre Geborek
Pierre Geborek
RVRonald F van Vollenhoven
Ronald F van Vollenhoven
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA). Methods In the SWEFOT trial, patients with RA with symptom duration <1 year started MTX monotherapy (20 mg/weekly) and 405/487 continued until the 3–4- month visit. The primary outcome measure was the DAS28-based European League against Rheumatism (EULAR) response criteria. Multivariate logistic regression was used to study the association between response and the following baseline characteristics: gender, age, symptom duration, cigarette smoking habits, autoantibody status, Health Assessment Questionnaire (HAQ) score, concurrent prednisolone and treatment with non-steroidal anti-inflammatory drugs. Secondary response and remission measures were the American College of Rheumatology and the Simple Disease Activity Index and Clinical Disease Activity Index (SDAI/CDAI)-derived criteria. Results After 3–4 months of MTX treatment, the frequency of EULAR good/moderate/no response was 34%/41%/25%, respectively. Parameters associated with a decreased likelihood of EULAR response were female gender (adjusted OR (adj OR) 0.50, 95% CI 0.31 to 0.81), symptom duration (adj OR per month increase 0.93, 95% CI 0.88 to 0.99), current smoking (adj OR 0.35, 95% CI 0.20 to 0.63) and higher HAQ (adj OR 0.56, 95% CI 0.40 to 0.80). Parameters associated with an increased likelihood of EULAR response were higher age (adj OR per 10-year increase 1.30, 95% CI 1.11 to 1.51) and prednisolone treatment (adj OR 2.84, 95% CI 1.43 to 5.63). The findings were similar when patients on prednisolone were excluded and other response criteria tested, although current smoking was the only significant predictor using all response criteria, while HAQ was the only significant predictor of all the remission criteria used. A matrix showed up to ninefold differences between subgroups stratified by the main predictors. Conclusion Current smoking, female sex, longer symptom duration and younger age predict a worse response to MTX in patients with new-onset RA. TrialRegNo NCT00764725